Revolution Medicines

Revolution Medicines is a clinical-stage precision oncology company that develops novel targeted therapies aimed at inhibiting challenging targets within critical growth and survival pathways, particularly the RAS and mTOR signaling pathways. Founded by Martin D. Burke, a professor at the University of Illinois, the company utilizes an innovative approach that reconfigures natural substances into advanced medicines. This method is based on a transformative synthesis technique that creates pharmaceutically optimized analogues of complex natural products. Revolution Medicines has entered into an exclusive license agreement with the University of Illinois to further develop this technology. Its product pipeline includes RMC-4630, a SHP2 inhibitor, as well as programs focused on the RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 pathways. Through its rapid and standardized process for assembling chemical building blocks into refined structures, the company aims to deliver best-in-class drug candidates with significant therapeutic potential.